PET Imaging of Microglia Using PBR28suv Determines Therapeutic Efficacy of Autologous Bone Marrow Mononuclear Cells Therapy in Traumatic Brain Injury

Authors

Supinder S Bedi
Michael C Scott
Max A Skibber
Akshita Kumar
Henry W Caplan
Hasen Xue
David Sequeira
Alison L Speer
Fanni Cardenas
Franciska Gudenkauf
Karen Uray
Amit K Srivastava
Alan R Prossin
Charles S Cox

Publication Date

9-26-2023

Journal

Scientific Reports

Abstract

Traumatic brain injury (TBI) results in activated microglia. Activated microglia can be measured in vivo by using positron emission topography (PET) ligand peripheral benzodiazepine receptor standardized uptake values (PBR28suv). Cell based therapies have utilized autologous bone marrow mononuclear cells (BMMNCs) to attenuate activated microglia after TBI. This study aims to utilize in vivo PBR28suv to assess the efficacy of BMMNCs therapy after TBI. Seventy-two hours after CCI injury, BMMNCs were harvested from the tibia and injected via tail-vein at 74 h after injury at a concentration of 2 million cells per kilogram of body weight. There were three groups of rats: Sham, CCI-alone and CCI-BMMNCs (AUTO). One hundred twenty days after injury, rodents were imaged with PBR28 and their cognitive behavior assessed utilizing the Morris Water Maze. Subsequent ex vivo analysis included brain volume and immunohistochemistry. BMMNCs therapy attenuated PBR28suv in comparison to CCI alone and it improved spatial learning as measured by the Morris Water Maze. Ex vivo analysis demonstrated preservation of brain volume, a decrease in amoeboid-shaped microglia in the dentate gyrus and an increase in the ratio of ramified to amoeboid microglia in the thalamus. PBR28suv is a viable option to measure efficacy of BMMNCs therapy after TBI.

Keywords

Animals, Rats, Microglia, Bone Marrow, Electrons, Brain Injuries, Traumatic, Positron-Emission Tomography

Comments

PMID: 37752232